Rosacea, Use of Tetracycline, and Risk of Incident Inflammatory Bowel Disease in Women

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 2, 2016, Pages 220-225.e3

  Li, Wen Qing ^a,b   Cho, Eunyoung ^a,b,c   Khalili, Hamed ^d   Wu, Shaowei ^a   Chan, Andrew T ^c,d   Qureshi, Abrar A ^a,b,c  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antibiotic; Dermatologic; NHS; Population; Side Effect

Indexed keywords

TETRACYCLINE; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; ROSACEA; SMOKING; TREATMENT DURATION; ULCERATIVE COLITIS; COMPLICATION; INFLAMMATORY BOWEL DISEASES; QUESTIONNAIRE; RISK ASSESSMENT;

ADULT; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; RISK ASSESSMENT; ROSACEA; SURVEYS AND QUESTIONNAIRES; TETRACYCLINE;

EID: 84958874775     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.09.013     Document Type: Article

References (28)

1. Elewski B.E., Draelos Z., Dreno B., et al. Rosacea: global diversity and optimized outcome-proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 2011, 25:188-200.
2. Steinhoff M., Schauber J., Leyden J.J. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol 2013, 69(Suppl 1):S15-S26.
3. Dosal J.R., Rodriguez G.L., Pezon C.F., et al. Effect of tetracyclines on the development of vascular disease in veterans with acne or rosacea: a retrospective cohort study. J Invest Dermatol 2014, 134:2267-2269.
4. Duman N., Ersoy Evans S., Atakan N. Rosacea and cardiovascular risk factors: a case control study. J Eur Acad Dermatol Venereol 2014, 28:1165-1169.
5. Spoendlin J., Voegel J.J., Jick S.S., et al. Risk of rosacea in patients with diabetes using insulin or oral antidiabetic drugs. J Invest Dermatol 2013, 133:2790-2793.
6. Li W.Q., Zhang M., Danby F.W., et al. Personal history of rosacea and risk of incident cancer among women in the United States. Br J Cancer 2015, 113:520-523.
7. Abraham C., Cho J.H. Inflammatory bowel disease. N Engl J Med 2009, 361:2066-2078.
8. Baumgart D.C., Carding S.R. Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369:1627-1640.
9. Li W.Q., Han J.L., Chan A.T., et al. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis 2013, 72:1200-1205.
10. Wakabayashi M., Fujimoto N., Uenishi T., et al. A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory bowel disease. Dermatology 2011, 222:231-235.
11. Baumgart D.C., Grittner U., Steingraber A., et al. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis 2011, 17:2512-2520.
12. Romiti R., Jansen T., Heldwein W., et al. Rosacea fulminans in a patient with Crohn's disease: a case report and review of the literature. Acta Derm Venereol 2000, 80:127-129.
13. van Steensel M.A., Badeloe S., Winnepenninckx V., et al. Granulomatous rosacea and Crohn's disease in a patient homozygous for the Crohn-associated NOD2/CARD15 polymorphism R702W. Exp Dermatol 2008, 17:1057-1058.
14. Crockett S.D., Porter C.Q., Martin C.F., et al. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol 2010, 105:1986-1993.
15. Racine A., Cuerq A., Bijon A., et al. Isotretinoin and risk of inflammatory bowel disease: a French nationwide study. Am J Gastroenterol 2014, 109:563-569.
16. Margolis D.J., Fanelli M., Hoffstad O., et al. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol 2010, 105:2610-2616.
17. Bernstein C.N., Nugent Z., Longobardi T., et al. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. Am J Gastroenterol 2009, 104:2774-2778.
18. Khalili H., Huang E.S., Ananthakrishnan A.N., et al. Geographical variation and incidence of inflammatory bowel disease among US women. Gut 2012, 61:1686-1692.
19. Loftus E.V., Silverstein M.D., Sandborn W.J., et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998, 114:1161-1168.
20. Loftus E.V., Silverstein M.D., Sandborn W.J., et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000, 46:336-343.
21. Chang A.L., Raber I., Xu J., et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol 2015, 135:1548-1555.
22. Goyette P., Boucher G., Mallon D., et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet 2015, 47:172-179.
23. Spoendlin J., Bichsel F., Voegel J.J., et al. The association between psychiatric diseases, psychotropic drugs and the risk of incident rosacea. Br J Dermatol 2014, 170:878-883.
24. Tan J., Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol 2013, 69(Suppl 1):S27-S35.
25. Ungaro R., Bernstein C.N., Gearry R., et al. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol 2014, 109:1728-1738.
26. Zhang M., Qureshi A.A., Fortner R.T., et al. Teenage acne and cancer risk in US women: a prospective cohort study. Cancer 2015, 121:1681-1687.
27. Tan J., Blume-Peytavi U., Ortonne J.P., et al. An observational cross-sectional survey of rosacea: clinical associations and progression between subtypes. Br J Dermatol 2013, 169:555-562.
28. Molodecky N.A., Soon I.S., Rabi D.M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54 e42. quiz e30.